Healio15h
VIVID-2: Omvoh demonstrates ‘continued durability,’ safety in Crohn’s disease at 2 years
Most patients with moderately to severely active Crohn’s disease who achieved endoscopic response and remission after 52 ...
Pharmabiz4d
Eli Lilly presents positive results from VIVID-2 open-label extension study of Omvoh to treat Crohn's disease at Crohn's and Colitis Congress
Eli Lilly and Company announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two years of ...
Business Insider7d
Eli Lilly announces results from VIVID-2 study
Eli Lilly (LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn’s disease receiving two years of ...